🎉 Pharmidex Celebrates Scientific Achievement! 🧪

January 27, 2025

We are thrilled to announce that members of the Pharmidex team have contributed to groundbreaking research, published in the prestigious journal International Journal of Molecular Sciences

📄 The paper, titled "Biomass-Derived Nanoporous Carbon Honeycomb Monoliths for Environmental Lipopolysaccharide Adsorption from Aqueous Media", explores innovative solutions for environmental challenges using advanced materials science.

👏 We extend our heartfelt congratulations and gratitude to all the authors for their dedication and hard work in bringing this important research to life.

🔗 Curious about the study? You can read the full article here: Read the Article (https://www.mdpi.com/1422-0067/26/3/952#)

We are proud to support and celebrate cutting-edge science that drives meaningful impact. Let’s continue pushing the boundaries of innovation! 🚀

#Pharmidex #Research #Innovation #Nanotechnology #Sustainability #Science

< Older Post

Newer Post >

🎓 Welcoming Future Scientists to Pharmidex! 🎓

July 28, 2025

We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. 👩‍🔬 👨‍🔬 Welcome to the team, Gabrielle and Mohammed!

Does your compound taste good enough for the clinic?

July 24, 2025

At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: ✅ Bitter-tasting APIs ✅ Unpalatable excipients ✅ The success of taste-masking strategies ✅ Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.

🔬 Now at Pharmidex: The 8HUM Model

July 21, 2025

Pharmidex is proud to offer access to the 8HUM model genetically humanized for 33 liver CYP enzymes responsible for metabolizing 90% of human drugs. ✅ Human-relevant metabolism data ✅ Supports IND-enabling ®gulatory studies ✅ Ideal for metabolite profiling, DDI risk & toxicity assessment By integrating 8HUM into our DMPK and in vivo studies, we deliver deeper, more predictive insights for safer, smarter drug development. 📩 Contact us to see how 8HUM can support your project.